Business
NetworkNewsWire Announces Publication on the Value of Cannabinoid-based Alternatives to Opioids
New York, New York--(Newsfile Corp. - December 18, 2017) - NetworkNewsWire - NetworkNewsWire...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication on the Value of Cannabinoid-based Alternatives to OpioidsNew York, New York--(Newsfile Corp. - December 18, 2017) - NetworkNewsWire - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain,\" highlights the escalating public health crisis of opioids and the push for pain management alternatives void of addictive components and reduced adverse side effects. To view the full publication, visit: https://www.networknewswire.com/dangerous-opioid-side-effects-shift-market-focus-cannabis-chronic-pain/InMed's proprietary biosynthesis technology, however, is a game changer, placing the ability to extract high yields of minor cannabinoids within the realm of commercial viability and unprecedented medical research.This is particularly key as the company advances its INM-405 candidate for the treatment of pain. Recent pre-clinical data from the company's pain treatment program (http://nnw.fm/4ICzO) suggests that topical application of certain non-THC cannabinoid compounds is effective in treating peripheral pain in craniofacial muscle pain disorders.This achievement builds on the company's proof-of-concept study results published earlier this year in the European Journal of Pain, suggesting that THC could reduce masticatory muscle pain through the activation of peripheral cannabinoid receptors CB1 and CB2, which are primary targets in the human body for cannabinoid drugs.About InMedInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are th...